We’re committed to meaningfully integrating sustainability considerations into our business practices and culture.
Clinical research and development is complex. Finding the right partner shouldn’t be.
The work we do has a global impact, and we are committed to making it a positive one. Our corporate sustainability practice enables us to engage meaningfully with stakeholders, empower our team members, reduce our environmental impact, and evolve our business model through innovation.
2019 Sustainability Report
PRA’s 2019 Corporate Sustainability report comes at an unprecedented time. Today, our world looks very different than it did when we began compiling…
Sustainable goals for a sustainable future.
We support the United Nations’ 17 Sustainable Development Goals, and our corporate goals align with three in particular:
- Health and Well-Being
- Gender Equality
- Industry Innovation and Infrastructure
We are also an IMPACT 2030 partner. IMPACT 2030 is a private sector, partnership-led initiative to achieve the UN’s goals. By working together, we believe we can make our world a healthier, more prosperous, and peaceful place.Read more about our partnership with IMPACT2030
Cross-Border Enrollment of Rare Disease Patients
Clinical trials in rare diseases present unique challenges unseen in trials for more common conditions. Cross-border enrollment can be key to…
Persistence Leads To High Enrollment
A Phase IV, randomized, single-blind, placebo-controlled, multi-center study to evaluate the immunogenicity of pneumococcal and influenza vaccines in…
Strategies for Accelerating Rare Disease Clinical Development
Rare disease trials differ from those in most other therapeutic areas because the indications are more complex and involve smaller patient…